Clinical Trial

Comparison of Efficacy and Safety Psoralen Combined With Ultraviolet A (PUVA) Vs Tofacitinib in the Treatment of Generalized Vitiligo.

Study acronym: (PUVA)
Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This study aims to compare the efficacy and safety of PUVA versus Tofacitinib in the treatment of generalized vitiligo. Given the high prevalence of vitiligo in Pakistan and the significant psychosocial impact on patients, particularly in Peshawar, this study will provide valuable insights into optimal treatment strategies.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-03; most recent amendment 2026-01-29.
Trial Details
NCT Number NCT07055529
Lead Sponsor Hayat Abad Medical Complex, Peshawar
Conditions Vitiligo, Generalized
Enrollment 64 participants
Start Date 2026-06-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-30